Passage Bio Inc

Passage Bio Inc (PASG) is a clinical-stage biotechnology company developing AAV-based gene therapies for rare monogenic central nervous system disorders. Investors should know the business is focused on scientific research and early-stage clinical development rather than current product sales, so revenue and profits are likely limited or non-existent. The company's small market capitalisation suggests limited liquidity and higher share-price volatility compared with larger peers. Key value drivers are clinical trial readouts, regulatory decisions and potential partnerships or licensing deals, all of which carry binary outcomes and long timelines. Development-stage biotechs often face substantial financing needs and dilution risk if they raise capital. For general education: this profile is not investment advice — gene therapy stocks can offer significant upside but also meaningful downside, and Passage Bio suits investors who understand biotech risk, can tolerate potential loss, and are prepared for a long investment horizon.